2月3日，三全食品发布投资者关系活动记录表。当中披露，关于公司2025年的表现，三全食品称，公司 产品端深入调研市场趋势，加强研究消费需求，积极与渠道伙伴共创产品，推出了"中国好饺子"、"多 多系列"水饺、"黄金比例饺子"、慢醒老面小笼包等新产品，在品质显著提升的同时保持极高的性价 比，获得了渠道及消费者的一致好评，新品收入实现快速增长。汤圆品类完善产品矩阵，食养汤圆三大 系列全面上新："养"主打药食同源理念，"润"针对女性消费需求，"珍"融入阿胶、燕窝等珍稀食材，同 时推出趣味造型汤圆、"低 GI"健康汤圆，满足不同画像消费者的需求。烤肠系列优化生产工艺，推 出"爆汁烤肠"等新产品，销售额快速增长，并实现市占率领先水平。肉卷、丸子等火锅食材产品在经过 调整后也表现出良好的增长势头，同时公司积极拓展西式产品赛道，意面系列产品上市后获得消费者广 泛好评。在渠道方面，公司直营渠道收入利润获得显著改善，收入降幅及利润亏损幅度持续大幅收窄， 经销渠道通过深化经销商服务及精细化管理，在优化经销商数量的同时单个经销商产出持续提高；社会 餐饮渠道抓住团餐业务增长契机，积极开拓团餐业务经销商，团餐业务规模持续扩大；公司持续加 ...

Core Viewpoint - The company, Tianbang Foods, has outlined its operational performance and future plans for its food segment, indicating a significant growth trajectory in its processed food business by 2025, while also addressing challenges in its slaughtering operations [1] Group 1: Operational Performance - The processed food sub-business is expected to see a sales increase of approximately 55% year-on-year in 2025, achieving profitability [1] - The slaughtering business is still ramping up production capacity and has not yet reached profitability [1] Group 2: Strategic Partnerships and Market Expansion - The company has established stable partnerships with major clients in the catering sector, including Tongqinglou, Laoxiangji, Gutian Daoxiang, and Bawan [1] - Tianbang Foods has successfully entered well-known national supermarkets such as Hema, JD.com, Yonghui Supermarket, and RT-Mart, effectively opening up the consumer market [1] Group 3: Future Plans - The company aims to enhance its breeding capacity to support the slaughtering business and improve slaughtering capacity utilization [1] - There is a focus on continuing innovation in processed products and market expansion, with the goal of making the food segment a significant profit growth point [1] - The company intends to leverage its full industry chain layout to strengthen overall profitability and operational stability [1]

Core Viewpoint - The company has made significant improvements in its direct sales channels through organizational optimization and data analysis, leading to enhanced management efficiency and profitability [1] Group 1: Direct Sales Channel Improvements - The company has implemented organizational optimization adjustments in its direct sales channels [1] - A multi-dimensional data analysis model has been adopted to significantly enhance management efficiency [1] - The company has strengthened the precision of channel operations and optimized expense allocation efficiency [1] Group 2: Collaboration and Customization - The company has adjusted its cooperation model to engage in "total-to-total" partnerships with major retail systems, improving channel service capabilities and collaboration efficiency [1] - Profitability has rapidly improved as a result of these adjustments [1] - The company is actively embracing customization opportunities by engaging in deep customization collaborations with major systems, leading to a rapid increase in the number and sales scale of customized products [1]

周生生 ang >ang NGTC 测试报告: | | | | | | | | | | 测试报告 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 样品名称 | | | | | | | | | 2.3-足金 | | | | | | | | | | 测试时间(s) | | | | | | | | | 10(=) | | | | | | | | | | 剥试日期 | | | | | | | | | 2026/2/3 14:57:25 | | | | | | | | | | 元素 | Cu (%) | Aca (%) | | A=(%) | | | Ni (6) | Pd(%) | Co (%) | | Pt (4) | Pe (V) | | Bu (N) | &(%) | Os (%) | Ir (b) | | 含量 | 0.00 | 99.99 | 0.00 | | 0.00 | | | 13.00 | ...

【中国国际啤酒网】1月30日，中国国务院关税税则委员会发布关于调整威士忌酒进口关税的公 告。当中披露，自2026年2月2日起，对威士忌酒实施5%的进口暂定税率。该商品归在《中华人民共和 国进出口税则（2026）》税则号列22083000项下。 ...

Core Viewpoint - Heng Rui Medicine (600276) has received a confirmation letter from the FDA regarding the acceptance of its biologics license application for injection of Carrelizumab combined with Apatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma patients [1] Group 1: Company Updates - The FDA has accepted the biologics license application for Carrelizumab, indicating progress in the company's drug development pipeline [1] - The total R&D investment for Carrelizumab-related projects has reached approximately 319.74 million yuan (unaudited) [1] Group 2: Industry Context - Several PD-1 monoclonal antibodies have been approved and are available in the market, including Pembrolizumab (Merck, brand name Keytruda), Nivolumab (Bristol-Myers Squibb, brand name Opdivo), Cemiplimab (Regeneron Pharmaceuticals, brand name Libtayo), and Dostarlimab (GlaxoSmithKline, brand name Jemperli) [1] - The global sales of anti-PD-1 antibodies are projected to reach approximately $41.546 billion in 2024 [1]

以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 2月3日，据中银理财披露，该公司发行的联阳合盈固收增强封闭式2026年02期认购期为2026年2月3日至 2026年2月9日。A类份额认购起点金额1元，募集规模5000万元。产品类型为固定收益类非保本浮动收 益型，产品期限373天。A类份额业绩比较基准为2.75%（年化）；B类份额业绩比较基准为2.80%（年 化）；C类份额业绩比较基准为2.85%（年化）。 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 ...

以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 2月3日，据北京农商银行披露，该行发行的金凤凰理财浓享骏马盈春封闭式固收增强2026年902期人民 币理财产品募集期为2026年2月3日-2026年2月12日。认购起点金额1万元起，产品规模不超过10亿元， 产品最低募集规模0.1亿元。产品类型为固定收益类、非保本浮动收益型，产品风险评级为R2较低风 险，产品期限396天，业绩比较基准2.35%-2.55%（年化）。 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 ...

以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 2月3日，据交银理财披露，该公司发行的稳享美元6个月QDII封闭式9号理财产品募集期为2026年2月3 日-2026年2月9日，投资起点金额为1美元。产品类型为固定收益类、非保本浮动收益型，产品风险评级 为低风险产品（R1），投资期限189天，业绩比较基准为3.13%-3.63%/年。 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 ...

智元机器人今日正式宣布，将于2月8日20:00全球直播全球首个大型机器人晚会《机器人奇妙夜》。作 为行业首创的机器人专属晚会，《机器人奇妙夜》最大亮点在于"全机器人主导"——两百余台机器人将 挑起大梁，包揽整场晚会的表演与观众互动。 2月8日20:00，观众可通过智元官方平台直播渠道同步观看，参与直播互动更有机会赢取惊喜好礼。 据透露，《机器人奇妙夜》将在芒果TV、智元AGIBOT官方平台及"稚晖君"全网账号同步直播，晚会内 容将挑战并刷新一系列行业"首创"纪录，展示交互智能、运动智能、作业智能与多机协同等前沿机器人 技术，以"最智能、有温度"的创新舞台，带来一场展现中国机器人实力的视听盛宴。这不仅是智元技术 集成能力的展现，更是推动机器人从"功能载体"向"文化参与者"乃至"情感表达者"演进的重要探索。 ...